Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile

Ellen Silbergeld, R. F. Pfeiffer

Research output: Contribution to journalArticle

Abstract

The ergolines are a new class of proposed dopamine receptor agonists, whose efficacy in treatment of Parkinsonism is under investigation. In order to explore the mechanisms of their action, two ergolines (bromocriptine and lergotrile) were compared to apomorphine for in vivo effects on behavior and in vitro effects on uptake and release of [3H]dopamine by brain minces. Inhibition of dopamine synthesis in vivo significantly interfered with both bromocriptine- and lergotrile-induced stereotype, while apomorphine-induced stereotype was not affected. Significant differences among the compounds were also seen neurochemically: bromocriptine inhibited the release of [3H]dopamine, while lergotrile increased release. Apomorphine did not affect uptake or release of [3H]dopamine. The results of both behavioral and neurochemical experiments, suggest that two ergolines enhance dopaminergic function by action on presynaptic dopaminergic sites in addition to receptor agonism.

Original languageEnglish (US)
Pages (from-to)1323-1326
Number of pages4
JournalJournal of Neurochemistry
Volume28
Issue number6
StatePublished - 1977
Externally publishedYes

Fingerprint

Ergolines
Bromocriptine
Apomorphine
Dopamine Agonists
Dopamine
Parkinsonian Disorders
Brain
lergotrile
Experiments

ASJC Scopus subject areas

  • Biochemistry
  • Cellular and Molecular Neuroscience

Cite this

Differential effects of three dopamine agonists : apomorphine, bromocriptine and lergotrile. / Silbergeld, Ellen; Pfeiffer, R. F.

In: Journal of Neurochemistry, Vol. 28, No. 6, 1977, p. 1323-1326.

Research output: Contribution to journalArticle

@article{e42601e6e27c4d0abf1e67ace9bb887e,
title = "Differential effects of three dopamine agonists: apomorphine, bromocriptine and lergotrile",
abstract = "The ergolines are a new class of proposed dopamine receptor agonists, whose efficacy in treatment of Parkinsonism is under investigation. In order to explore the mechanisms of their action, two ergolines (bromocriptine and lergotrile) were compared to apomorphine for in vivo effects on behavior and in vitro effects on uptake and release of [3H]dopamine by brain minces. Inhibition of dopamine synthesis in vivo significantly interfered with both bromocriptine- and lergotrile-induced stereotype, while apomorphine-induced stereotype was not affected. Significant differences among the compounds were also seen neurochemically: bromocriptine inhibited the release of [3H]dopamine, while lergotrile increased release. Apomorphine did not affect uptake or release of [3H]dopamine. The results of both behavioral and neurochemical experiments, suggest that two ergolines enhance dopaminergic function by action on presynaptic dopaminergic sites in addition to receptor agonism.",
author = "Ellen Silbergeld and Pfeiffer, {R. F.}",
year = "1977",
language = "English (US)",
volume = "28",
pages = "1323--1326",
journal = "Journal of Neurochemistry",
issn = "0022-3042",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Differential effects of three dopamine agonists

T2 - apomorphine, bromocriptine and lergotrile

AU - Silbergeld, Ellen

AU - Pfeiffer, R. F.

PY - 1977

Y1 - 1977

N2 - The ergolines are a new class of proposed dopamine receptor agonists, whose efficacy in treatment of Parkinsonism is under investigation. In order to explore the mechanisms of their action, two ergolines (bromocriptine and lergotrile) were compared to apomorphine for in vivo effects on behavior and in vitro effects on uptake and release of [3H]dopamine by brain minces. Inhibition of dopamine synthesis in vivo significantly interfered with both bromocriptine- and lergotrile-induced stereotype, while apomorphine-induced stereotype was not affected. Significant differences among the compounds were also seen neurochemically: bromocriptine inhibited the release of [3H]dopamine, while lergotrile increased release. Apomorphine did not affect uptake or release of [3H]dopamine. The results of both behavioral and neurochemical experiments, suggest that two ergolines enhance dopaminergic function by action on presynaptic dopaminergic sites in addition to receptor agonism.

AB - The ergolines are a new class of proposed dopamine receptor agonists, whose efficacy in treatment of Parkinsonism is under investigation. In order to explore the mechanisms of their action, two ergolines (bromocriptine and lergotrile) were compared to apomorphine for in vivo effects on behavior and in vitro effects on uptake and release of [3H]dopamine by brain minces. Inhibition of dopamine synthesis in vivo significantly interfered with both bromocriptine- and lergotrile-induced stereotype, while apomorphine-induced stereotype was not affected. Significant differences among the compounds were also seen neurochemically: bromocriptine inhibited the release of [3H]dopamine, while lergotrile increased release. Apomorphine did not affect uptake or release of [3H]dopamine. The results of both behavioral and neurochemical experiments, suggest that two ergolines enhance dopaminergic function by action on presynaptic dopaminergic sites in addition to receptor agonism.

UR - http://www.scopus.com/inward/record.url?scp=0017656747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017656747&partnerID=8YFLogxK

M3 - Article

C2 - 577501

AN - SCOPUS:0017656747

VL - 28

SP - 1323

EP - 1326

JO - Journal of Neurochemistry

JF - Journal of Neurochemistry

SN - 0022-3042

IS - 6

ER -